Shares of COVID-19 vaccine developers rose on Monday after the FDA issued briefing documents for its Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting on Jun 5 to consider the selection of the 2024-2025 formula for COVID-19 vaccines.In this meeting, members of the VRBPAC will discuss whether to update the currently authorized COVID-19 vaccines to target the JN.1 variant. This was also recommended by a World Health Organization (WHO) advisory committee on Apr 26.The FDA pointed out ...